Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp registers 2,710,945 ordinary shares issuable upon exercise of outstanding warrants under a combined post-effective amendment converting two prior registration statements to Form S-3. These shares consist of Series A, Series B, January 2025 and placement agent warrants exercisable at specified prices and expirations, and the Company states it would receive gross proceeds of approximately $11.86 million if all such warrants are exercised for cash. The filing updates prospectus terms, exercise limitations (including 4.99%/9.99% beneficial-ownership caps), exercise prices ranging from $4.00 to $25.31, and lists share counts of 4,074,710 outstanding prior to the offering and a pro forma 6,785,655 shares assuming full exercise.
Silexion Therapeutics Corp files Post-Effective Amendments converting prior S-1 registrations into a combined Form S-3 prospectus to register up to 2,710,945 ordinary shares issuable upon exercise of outstanding warrants. The prospectus lists 1,500,000 Series A, 1,055,000 Series B, 33,661 January 2025 ordinary warrants and placement agent warrants totaling 122,284. The filing states that, if all such warrants are exercised for cash, the company would receive gross proceeds of approximately $11.86 million, and that ordinary shares outstanding were 4,074,710 as of May 6, 2026. The registration is intended to enable issuance of shares upon warrant exercise and will become effective in accordance with Section 8(a) of the Securities Act.
Silexion Therapeutics Corp held a reconvened extraordinary general meeting on May 5, 2026, where shareholders approved several capital structure changes. The key step was a Memorandum Amendment increasing authorized share capital from US$121,500, divided into 9,000,000 ordinary shares, to US$796,500, divided into 59,000,000 ordinary shares, each with a par value of US$0.0135. Shareholders also approved an evergreen increase and a reverse share split proposal. The meeting proceeded after 1,638,079 ordinary shares, representing about 40.2% of issued and outstanding shares, constituted a quorum under the company’s articles. Each proposal received around 61% of votes cast in favor, meeting the simple majority threshold.
Silexion Therapeutics Corp furnished an update that it has successfully submitted a Clinical Trial Application in Germany for a planned Phase 2/3 trial of its lead siRNA therapy, SIL204, in KRAS-driven locally advanced pancreatic cancer. Germany will act as the Reporting Member State for the European Union review under the CTIS system, following earlier approval from the Israeli Ministry of Health for the same Phase 2/3 trial. The company plans to start the global Phase 2/3 study in the second quarter of 2026, combining intratumoral and systemic administration of SIL204 with standard chemotherapy at leading oncology centers in Germany, other EU states and Israel.
Silexion Therapeutics Corp is asking shareholders to approve three major capital-structure changes at an extraordinary general meeting on April 28, 2026. The board wants to increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, citing a lack of unissued shares and the need to maintain at least $2.5 million of shareholders’ equity required by Nasdaq.
A second proposal would amend the 2024 Equity Incentive Plan’s evergreen provision so that, each January 1, the pool reserved under all equity plans equals 10% of issued and outstanding shares on a fully diluted basis, up from a 5% of outstanding-shares formula. The third proposal authorizes a reverse share split of all ordinary shares, at a ratio between 1‑for‑4 and 1‑for‑10, to help keep the Nasdaq bid price above $1.00 and avoid potential delisting, without changing each holder’s percentage ownership aside from minor rounding of fractional shares.
Silexion Therapeutics Corp CSO and CDO Shirvan Mitchell reported an open-market sale of 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. According to the footnotes, this was a sale-to-cover transaction to pay tax liabilities from a fully vested restricted share unit grant received on February 20, 2026.
After the sale, Mitchell directly held 27,889 Ordinary Shares. He also held a stock option over 478 Ordinary Shares with an exercise price of $907.71 per share and an expiration date of June 7, 2032, adjusted to reflect prior reverse share splits.
Silexion Therapeutics Corp reported a boardroom change, noting that its Board of Directors removed Ilan Levin from his role as a director, effective immediately on March 25, 2026. The remaining board members acted unanimously by written determination under Article 28.7 of the company’s Amended and Restated Articles of Association.
Silexion Therapeutics Corp reports that the Israeli Ministry of Health has formally approved a Phase 2/3 clinical trial of its RNAi therapy SIL204 in locally advanced pancreatic cancer. SIL204 is designed to silence a broad range of KRAS mutations, which occur in over 90% of pancreatic cancers, and has shown significant anti-tumor activity in multiple preclinical models with supportive toxicology data. The company expects to begin the Phase 2/3 trial in the second quarter of 2026, subject to site activation and standard readiness steps, and plans additional regulatory filings in Germany by the end of the current quarter and across the European Union in early 2027.